Latest revenue
—
as of 2025-06-30
Latest net income
$-8.5M
as of 2025-06-30
Net margin
—
as of 2025-06-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ANEB is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $15.9M
- Enterprise value
- $7.1M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 2.00×
- Dividend yield
- 0.0%
- 52-wk high
- $3.42
- 52-wk low
- $0.30
- Beta
- —
- Shares out
- 40.8M
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage pharmaceutical company developing treatments for cannabis-induced toxicity, such as acute cannabis-induced toxicity in children, acute cannabinoid intoxication (“ACI”) and the broader landscape of acute cannabis-induced conditions. Our lead product candidate, selonabant (formerly ANEB-001), is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. Pediatric patients exposed to cannabis are at risk of serious and life-threatening outcomes including Central Nervous System (“CNS”) depression, respiratory depression, seizures, and coma. ACI in adults is characterized by signs and symptoms that…
AI summary unavailable — showing raw filing excerpt
Generated from ANEB's filing dated 2025-09-29
Key risks
Item 1A. Risk Factors The following risk factors and other information included in this Annual Report on Form 10-K should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. Risks Related to our Business, Financial Condition and Capital Requirements We have not generated any revenue since our inception and expect to incur future losses…
AI summary unavailable — showing raw filing excerpt
Generated from ANEB's filing dated 2025-09-29
Profitability
Return on equity
-72.8%
66.2%Return on assets
-69.9%
65.3%Leverage
Debt / equity
0.04×
38.8%Debt / assets
4.0%
37.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $-2.0M | +18.8% | — |
Q3 2025 2025-09-30 | — | — | $-2.2M | +1.9% | — |
Q2 2025 2025-06-30 | — | — | $-2.1M | -58.9% | — |
Q1 2025 2025-03-31 | — | — | $-1.7M | -1.4% | — |
Q4 2024 2024-12-31 | — | — | $-2.5M | +9.4% | — |
Q3 2024 2024-09-30 | — | — | $-2.2M | +11.3% | — |
Q2 2024 2024-06-30 | — | — | $-1.3M | — | — |
Q1 2024 2024-03-31 | — | — | $-1.7M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ANEB — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for ANEB in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns ANEB
Institutional value
$91.6M
Total shares held
22.2M
Distinct holders
19
-2 vs prior
As of
2025-12-31
Prior: 2025-09-30
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | 22NW, LP | 15.5M | $84.8M | +0 (+0.0%) | No change |
| 2 | Nantahala Capital Management, LLC | 3.0M | $3.1M | +0 (+0.0%) | No change |
| 3 | MANGROVE PARTNERS IM, LLC | 2.5M | $2.6M | +0 (+0.0%) | No change |
| 4 | VANGUARD GROUP INC | 435.8K | $440.2K | +129.3K (+42.2%) | Added |
| 5 | MORGAN STANLEY | 399.4K | $403.4K | +0 (+0.0%) | No change |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 160.8K | $162.5K | -13.3K (-7.7%) | Trimmed |
| 7 | Rangeley Capital, LLC | 50.0K | $50.5K | +30.0K (+150.0%) | Added |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 25.1K | $25.3K | -3.4K (-11.9%) | Trimmed |
| 9 | CITADEL ADVISORS LLC | 24.2K | $24.5K | — | New |
| 10 | BlackRock, Inc. | 23.8K | $24.0K | -270 (-1.1%) | Trimmed |
| 11 | NORTHERN TRUST CORP | 22.0K | $22.2K | -2.4K (-9.8%) | Trimmed |
| 12 | Ikarian Capital, LLC | 17.7K | $17.9K | -140.0K (-88.8%) | Trimmed |
| 13 | STATE STREET CORP | 12.8K | $12.9K | +0 (+0.0%) | No change |
| 14 | Tower Research Capital LLC (TRC) | 3.2K | $3.3K | +1.5K (+84.6%) | Added |
| 15 | UBS Group AG | 2.3K | $2.4K | +2.1K (+960.9%) | Added |
| 16 | JPMORGAN CHASE & CO | 2.3K | $2.3K | -2.0K (-47.3%) | Trimmed |
| 17 | BANK OF AMERICA CORP /DE/ | 382 | $386 | -1.4K (-78.6%) | Trimmed |
| 18 | Royal Bank of Canada | 30 | $0 | — | New |
| 19 | FNY Investment Advisers, LLC | 100 | $0 | +5 (+5.3%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ANEB's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.